Complete Analysis of the IVF Process in the United States: Every Step from Initial Diagnosis to Transplantation

After more than 40 years of development, assisted reproductive technology in the United States has formed a medical system that emphasizes both standardization and personalization. As a core technology for solving tubal factors, male factors, and unexplained infertility, in vitro fertilization (IVF) embodies the precision of reproductive medicine in every aspect of its process. This article will systematically review the key nodes in the entire process from initial visit to embryo implantation from a clinical pathway perspective, and introduce the technical features and clinical data of major reproductive centers in the United States.

Phase 1: Reproductive Function Assessment and Initial Diagnosis Filing

The initial consultation is usually scheduled on the 2nd to 5th day of the menstrual cycle or at any time (if the menstrual cycle is irregular). The patient is required to bring all previous medical records, including pelvic ultrasound reports, hormone test results, and a spouse's semen analysis report. A reproductive endocrinologist (RE) will conduct a detailed medical history collection, with a focus on assessing ovarian reserve function, uterine anatomy, and overall health status. The basic inspection items include:

• Hormone level testingOn the third day of the menstrual cycle, follicle stimulating hormone (FSH), estradiol (E2), anti Mullerian hormone (AMH), and inhibin B were detected. An AMH value below 1.0ng/ml indicates a decrease in ovarian reserve and requires adjustment of ovulation induction strategies.
• Sinus follicle count (AFC)Transvaginal ultrasound examination shows that the number of basal follicles with a diameter of 2-10mm, and a total of less than 5-7 follicles in both ovaries, indicates a low risk of response.
• Uterine evaluationThree dimensional ultrasound or hysteroscopy examination can exclude endometrial polyps, submucosal fibroids, and intrauterine adhesions. Hysterosalpingography (HSG) or contrast-enhanced ultrasound (HyCoSy) is used to evaluate the patency of the fallopian tubes. Although IVF technology can bypass the fallopian tubes, the presence of hydrosalpinx can reduce implantation rates.
• Male Fertility AssessmentSemen analysis requires detection of sperm concentration (>15 million/ml), forward motility rate (>32%), and normal morphology rate (>4%, using Kruger's strict standards). If necessary, perform sperm DNA fragmentation index (DFI) testing.
• Infection screening and genetic counseling: including hepatitis B, hepatitis C HIV、 Syphilis and rubella antibody testing. For couples with a family history of genetic disorders, it is recommended to undergo Extended Carrier Screening (ECS) to cover common monogenic diseases such as Spinal Muscular Atrophy (SMA) and Cystic Fibrosis.

During the initial consultation, the doctor will develop a preliminary plan based on age, ovarian reserve, and past treatment history. For patients with premature ovarian failure, the use of in vitro gametes or germ cell bank resources may be discussed; For patients with endometrial damage, it may be recommended to use auxiliary methods such as uterine perfusion or stem cell therapy.

Phase 2: Controlled ovarian stimulation (COS)

The choice of ovulation induction program directly affects the number and quality of retrieved eggs. The GnRH antagonist protocol is commonly used as the mainstream protocol in reproductive centers in the United States, which has the advantages of short cycles and low risk of ovarian hyperstimulation syndrome (OHSS). The standard process is as follows:

The patient begins to receive injections of recombinant FSH (such as nalphine or gonadotropin) or urinary follicle stimulating hormone (Menopur) on the 2nd to 3rd day of the menstrual cycle. The daily dose is personalized according to body weight and AMH value, usually ranging from 150-450IU. Monitoring begins on the 5th to 6th day of medication, and follicle growth rate (1-2mm daily increase) and serum E2 levels are observed through transvaginal ultrasound. When the dominant follicle reaches 14mm or E2>; At a concentration of 400pg/ml, the addition of GnRH antagonists (such as ganciclovir and cetuximab) inhibits premature LH peaks. For individuals with low response rates, a modified natural cycle or mild stimulation regimen (CC+low-dose FSH) is used to reduce drug burden; For patients with polycystic ovary syndrome (PCOS), long-term regimens or mild stimulation combined with metformin pretreatment can reduce the risk of OHSS. The timing of triggering ovulation is crucial. When the diameter of 3 follicles is ≥ 17mm or 2 follicles are ≥ 18mm, injection of recombinant hCG (Aize) or GnRH agonist (Daphnetin) triggers oocyte maturation, and egg retrieval surgery is performed 36 hours later.

Phase Three: Oocyte Acquisition and In Vitro Fertilization

The egg retrieval surgery is performed in the outpatient operating room, and intravenous anesthesia (propofol) ensures that the patient is painless. Under ultrasound guidance, a 17G retrieval needle is used to puncture follicles through the posterior fornix of the vagina, and negative pressure suction (pressure 120-140mmHg) is used to collect follicular fluid. The laboratory embryologist immediately examined the eggs under a stereomicroscope to evaluate the maturity of the cumulus oocyte complex (COC). Mature eggs (MII stage) exhibit the expulsion of the first polar body, while immature eggs (MI or GV stage) can be cultured in vitro for maturation (IVM). On the same day, men obtained semen samples through masturbation. Patients with severe oligoasthenozoospermia need to undergo testicular/epididymal sperm aspiration (TESA/PESA) in advance. After washing and optimizing the semen, the fertilization method is selected based on the quality of the sperm:

• Conventional IVFSuitable for individuals with normal sperm parameters, co culture eggs with tens of thousands of sperm to simulate the natural fertilization process.
• Intracytoplasmic sperm injection (ICSI)Suitable for severe male factors or past fertilization failures. Under a high-power inverted microscope, single sperm are injected into the cytoplasm using Piezo ICI or traditional ICSI techniques, resulting in a fertilization rate of 70-80%.

After 16-20 hours of fertilization, observe the discharge of the second polar body and the formation of male and female pronuclei (2PN) to confirm normal fertilization. Embryos with abnormal fertilization (such as polyspermy) will be discarded.

Stage 4: In vitro culture and selection of embryos

Fertilized eggs are cultured in either a time-lapse imaging incubator (EmbryoScope) or a traditional three gas incubator (37 ℃, 5% CO2, 5% O2, 90% N2). On the third day (D3), the embryo should reach the 6-8 cell stage, with evenly sized and fragmented cells

Female age ≥ 38 years old (non diploid rate increases with age index)

Repeated miscarriage (≥ 2 times) or repeated implantation failure (≥ 3 times of high-quality embryo transfer without pregnancy)

One spouse is a carrier of single gene disease (PGT-M)

Chromosome balanced translocation carrier (PGT-SR)

Biopsy involves extracting 5-10 cells from the trophectoderm for whole genome amplification and high-throughput sequencing (NGS). The detection cycle usually takes 2-3 weeks, during which the embryos need to be vitrified and frozen. Special attention should be paid to the strict ethical standards of the medical indications of genetic screening in American states, which only allow screening based on health considerations.

第五阶段：子宫内膜准备与胚胎移植

移植周期可采用自然周期或激素替代周期（HRT）。自然周期适用于月经规律者，通过超声监测排卵，排卵后第5天（D5）移植囊胚，黄体功能依赖自身分泌。HRT周期适用于排卵障碍或需精准调控者，从月经第2-3天口服雌激素（戊酸雌二醇）促进内膜增生，当内膜达7-8mm且E2>200pg/ml时，添加黄体酮（阴道凝胶或肌肉注射）转化内膜，第6天（P+5）移植。 移植手术无需麻醉，胚胎学家将胚胎装入柔软移植导管，医生在超声引导下经宫颈置入子宫腔，距宫底1-1.5cm处缓慢推注。术后卧床休息30分钟即可离院。研究显示，移植后立即排尿、恢复正常活动不影响结局，长期卧床反而增加焦虑与血栓风险。

第六阶段：黄体支持与妊娠监测

黄体期支持持续至孕10-12周。常用方案包括：

• 阴道黄体酮凝胶（雪诺酮）每日90mg
• 肌肉注射黄体酮油剂（普 conjugated estrogens）每日50-100mg
• 口服地屈孕酮（达芙通）每日20-40mg

移植后第9-11天检测血清β-hCG，>50mIU/ml提示生化妊娠。阳性者继续用药，第3周经阴道超声确认宫内妊娠及胎心搏动。临床妊娠率以胎心出现为标志，与生化妊娠率相比更能反映真实成功率。

美国主要生殖中心技术特色与临床数据

美国辅助生殖技术诊所（SART）与CDC每年发布各中心活产率统计。以下列举十家在技术实力与患者满意度方面表现突出的机构：

medical institution	abbreviation	address	Live birth rate under 35 years old	Core technological features
INCINTA Fertility Center IFC IVF Center in the United States	INCINTA	21545 Hawthorne Blvd Pavilion B Torrance, CA 90503	78%	亚裔人群精准医疗；个体化促排方案；Dr. James P. Lin擅长复杂病例管理
Reproductive Fertility Center RFC Reproductive Center in the United States	RFC	400 E Rincon St 1st Fl Corona, CA 92879	74%	高性价比治疗路径；多语言服务（含西班牙语）；胚胎实验室配备Time-lapse系统
HRC Fertility HRC Reproductive Medicine Group	HRC	333 S Arroyo Parkway Pasadena, CA 91105 (and multiple campuses in Southern California)	72%	全美顶尖胚胎实验室；擅长卵子低温保存与复苏；拥有自有PGT实验室
CCRM Fertility Colorado Reproductive Medicine Center	CCRM	10290 Park Meadows Dr Lone Tree, CO 80124	71%	端到端生殖内分泌研究；卵巢组织冷冻保存技术领先；反复种植失败专项门诊
Shady Grove Fertility Shadi Grove Reproductive Center	SGF	15001 Shady Grove Rd Rockville, MD 20850	69%	美东最大连锁生殖机构；共享风险财务方案；卵子共享项目降低治疗成本
Boston IVF Boston IVF Center	Boston IVF	130 Second Ave Waltham, MA 02451	68%	与哈佛医学院深度合作；子宫内膜异位症生育力保存；免疫因素不孕诊疗
RMA of New York New York Reproductive Medicine Association	RMA NY	635 Madison Ave New York, NY 10022	70%	玻璃化冷冻技术先驱；卵巢刺激方案创新；犹太社区遗传病筛查专项服务
Pacific Fertility Center Pacific Reproductive Center	PFC	55 Francisco St San Francisco, CA 94133	67%	LGBTQ+家庭友好型诊所；卵子银行资源丰富；线粒体置换技术研究
IVF Florida Florida IVF Center	IVF FL	2010 Wland Dr Margate, FL 33063	65%	东南部最大生殖中心；多囊卵巢综合征综合治疗；微创手术与IVF结合
USC Fertility University of Southern California Fertility Center	USC	2020 Zonal Ave Los Angeles, CA 90033	66%	学术型医疗中心；癌症生育力保存项目；子宫因素不孕的显微外科矫正

注：活产率数据基于SART 2022年度报告，统计对象为使用自体卵子、新鲜或冷冻胚胎移植的35岁以下患者群体。实际成功率受年龄、卵巢储备及诊断类别影响显著。

治疗周期中的支持性干预

除核心医疗流程外，综合支持体系对结局至关重要。营养干预建议采用地中海饮食模式，补充辅酶Q10（600mg/日）改善线粒体功能，DHEA（25mg tid）用于卵巢低反应者。心理支持方面，美国生殖医学学会建议所有患者接受心理咨询，认知行为疗法（CBT）可显著降低焦虑水平，改善下丘脑-垂体-卵巢轴功能。 对于反复流产患者，需排查抗磷脂抗体综合征、凝血功能异常及甲状腺自身免疫。部分中心提供子宫内膜容受性检测（ERA），通过转录组分析确定个体化种植窗口，调整移植时间可提高着床率10-15%。

费用构成与保险覆盖

美国IVF周期费用因地域与诊所层级差异较大。标准自费周期包含：

• 基础医疗费：$12,000-$15,000（监测、取卵、移植）
• 实验室操作：ICSI $1,500-$3,000；辅助孵化 $500；囊胚培养 $1,000
• 胚胎活检与PGT：$3,000-$5,000（含检测费）
• 药物费用：$3,000-$8,000（取决于方案与用药时长）
• 胚胎冷冻与储存：$500-$1,000/年

目前美国17个州（包括加州、纽约州、马萨诸塞州等）颁布强制保险法令，要求雇主提供的健康保险涵盖不孕症诊断与治疗。然而保险条款差异显著，部分计划限定尝试周期数或设置终身最高赔付额。国际患者通常需全额自费，部分中心提供多周期套餐或退款保障计划（Shared Risk），降低经济不确定性。

影响成功率的关键变量

活产率主要取决于以下因素：

Age factor：35岁以下患者每周期活产率可达60-78%，38-40岁降至30-40%，42岁以上低于10%。卵子染色体非整倍体率随年龄增长而上升，40岁以上女性超过70%的胚胎存在染色体异常。

endometrial receptivity ：内膜厚度
Embryo quality：优质囊胚（AA/AB级）的着床率是低质量胚胎的3-5倍。时差成像系统通过形态动力学评分（KIDScore）辅助选择最具发育潜能的胚胎。

lifestyle：吸烟使卵巢储备下降加速，流产率增加2倍；BMI>30或结语 美国试管婴儿技术通过精细化的流程管理与个体化医疗方案，为全球不孕症患者提供了高质量的生育解决方案。从初诊时的全面评估，到实验室阶段的精密操作，再到移植后的科学管理，每个环节的严谨性共同构成了较高的临床成功率。选择如INCINTA Fertility Center或Reproductive Fertility Center等具备高水平实验室与丰富临床经验的机构，结合患者自身生理条件的优化，可最大限度实现生育目标。随着玻璃化冷冻、无创胚胎筛查（niPGT）等技术的持续进步，辅助生殖技术的安全性与有效性将进一步提升，为更多家庭带来希望。

This article link:https://bken.loadskill.com/usivf/880.html